Comparison of antitumor activities of pancreatic ribonuclease and its cross-linked dimer.
The cross-linked dimer of bovine pancreatic RNase (M.W. 28,000) is significantly more effective than the monomer in inhibiting tumor development in mice when administered i.p. 1 day after inoculation with sarcoma 180J ascites cells. Animals bearing solid tumors were not affected. In AKR/J mice with advanced leukemia, a single i.p. injection of 100 mug of the dimer led to about 50% reduction in the enlarged lymph nodes and the spleen at 24 hr. The half-life of the dimer in the bloodstream has been determined to be 10 min in rats and 6 min in mice, compared to values of 5 and 3.5 min, respectively, for the monomer. Analyses of the tissues of untreated leukemic mice for RNase and RNase inhibitors show that the tumor tissues are not deficient in RNase activity. Considerations of possible mechanisms of action of the dimer indicate that other basic proteins in this size range may merit examination as cytostatic agents toward transformed cells.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000378:metabolism; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000473:pathology; D006207:Half-Life; D006984:Hypertrophy; D066298:In Vitro Techniques; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000473:pathology; D008198:Lymph Nodes / Q000201:enzymology / Q000473:pathology; D051379:Mice; D008806:Mice, Inbred AKR; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D012260:Ribonucleases / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D012510:Sarcoma 180 / Q000188:drug therapy / Q000473:pathology; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000473:pathology; D013154:Spleen / Q000201:enzymology / Q000473:pathology
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D012260:Ribonucleases